CPT1 Deficiency Update - ANTHC

More documents

Recommendations

Info

Summary • 7% of Alaska infants are homozygous for the C1436T sequence variant (P479L) • Newborn screening identified only _% of affected infants in this sample • Newborn screening by MS/MS is not an effective means to identify infants with <strong>CPT1</strong>A deficiency due to the P479L variant
The Big Questions: • What is the clinical impact of the P479L sequence variant ? • What is the true incidence of <strong>CPT1</strong>A deficiency in Alaska • Do we need to identify and treat affected infants ?
Page 1 and 2: Carnitine Palmitoyltransferase 1A D
Page 3 and 4: CPT1 is required for the import of
Page 5 and 6: In the presence of an adequate gluc
Page 7 and 8: Regulation of CPT1 activity
Page 9 and 10: Goals • CPT1A • CPT1A deficienc
Page 11 and 12: CPT1A Deficiency: Treatment • Avo
Page 13 and 14: Newborn Screening for CPT1A Deficie
Page 17 and 18: The Big Questions: • What is the
Page 19 and 20: Retrospective genotyping of newborn
Page 21 and 22: Summary • There is evidence sugge
Page 23 and 24: Previous Reports of the P479L varia
Page 25 and 26: Due to concern that routine newborn
Page 27 and 28: Results: • The P479L variant is d
Page 29: C0/ (C16 + C18) MS/MS data for all
Page 33 and 34: Infant Mortality Rates (1992-2004)
Page 37 and 38: Ongoing Studies • Impact of CPT1A
Page 39: Acknowledgements • Alaska DHSS -

CPT1 Deficiency Update - ANTHC

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?